0 CHECKOUT

Metastatic Breast Cancer - Pipeline Review, H1 2015

  • ID: 3345023
  • June 2015
  • 866 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Biocon Limited
  • Galileo Research s.r.l.
  • Johnson & Johnson
  • Morphotek, Inc.
  • Pharma Mar, S.A.
  • MORE

Metastatic Breast Cancer - Pipeline Review, H1 2015

Summary

the, ‘Metastatic Breast Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Breast Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Biocon Limited
  • Galileo Research s.r.l.
  • Johnson & Johnson
  • Morphotek, Inc.
  • Pharma Mar, S.A.
  • MORE

Introduction
Metastatic Breast Cancer Overview
Therapeutics Development
Metastatic Breast Cancer - Therapeutics under Development by Companies
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Breast Cancer - Pipeline Products Glance
Metastatic Breast Cancer - Products under Development by Companies
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes
Metastatic Breast Cancer - Companies Involved in Therapeutics Development
Metastatic Breast Cancer - Therapeutics Assessment
Drug Profiles
Metastatic Breast Cancer - Recent Pipeline Updates
Metastatic Breast Cancer - Dormant Projects
Metastatic Breast Cancer - Discontinued Products
Metastatic Breast Cancer - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Metastatic Breast Cancer, H1 2015
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Metastatic Breast Cancer - Pipeline by AbbVie Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015
Metastatic Breast Cancer - Pipeline by AlphaVax, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2015
Metastatic Breast Cancer - Pipeline by Amgen Inc., H1 2015
Metastatic Breast Cancer - Pipeline by AngioGenex, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Aphios Corporation, H1 2015
Metastatic Breast Cancer - Pipeline by arGEN-X BV, H1 2015
Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H1 2015
Metastatic Breast Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Bavarian Nordic A/S, H1 2015
Metastatic Breast Cancer - Pipeline by Bayer AG, H1 2015
Metastatic Breast Cancer - Pipeline by BIOCAD, H1 2015
Metastatic Breast Cancer - Pipeline by Biocon Limited, H1 2015
Metastatic Breast Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015
Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Celgene Corporation, H1 2015
Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015
Metastatic Breast Cancer - Pipeline by Curadis GmbH, H1 2015
Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015
Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H1 2015
Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H1 2015
Metastatic Breast Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Etubics Corporation, H1 2015
Metastatic Breast Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Galileo Research s.r.l., H1 2015
Metastatic Breast Cancer - Pipeline by Genentech, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015
Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H1 2015
Metastatic Breast Cancer - Pipeline by GTx, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Hospira, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Immune Design Corp., H1 2015
Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Immupharma Plc, H1 2015
Metastatic Breast Cancer - Pipeline by Imugene Limited, H1 2015
Metastatic Breast Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Incyte Corporation, H1 2015
Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H1 2015
Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H1 2015
Metastatic Breast Cancer - Pipeline by Kancera AB, H1 2015
Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2015
Metastatic Breast Cancer - Pipeline by Mabion SA, H1 2015
Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by MandalMed, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Meabco A/S, H1 2015
Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H1 2015
Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Merck KGaA, H1 2015
Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Merus B.V., H1 2015
Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H1 2015
Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H1 2015
Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H1 2015
Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Novartis AG, H1 2015
Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015
Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Oncobiologics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015
Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Oncothyreon Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015
Metastatic Breast Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Pfizer Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H1 2015
Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Radius Health, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Samyang Holdings Corporation, H1 2015
Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H1 2015
Metastatic Breast Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Metastatic Breast Cancer - Pipeline by Theracrine, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2015
Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H1 2015
Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2015
Metastatic Breast Cancer - Pipeline by Verastem, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015
Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Wilex AG, H1 2015
Metastatic Breast Cancer - Pipeline by WntResearch AB, H1 2015
Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H1 2015
Metastatic Breast Cancer - Pipeline by Zyngenia, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Metastatic Breast Cancer - Dormant Projects, H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..1), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..2), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..3), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..4), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..5), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..6), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..7), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..8), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..9), H1 2015
Metastatic Breast Cancer - Dormant Projects (Contd..10), H1 2015
Metastatic Breast Cancer - Discontinued Products, H1 2015
Metastatic Breast Cancer - Discontinued Products (Contd..1), H1 2015
Metastatic Breast Cancer - Discontinued Products (Contd..2), H1 2015
Metastatic Breast Cancer - Discontinued Products (Contd..3), H1 2015
Metastatic Breast Cancer - Discontinued Products (Contd..4), H1 2015

List of Figures
Number of Products under Development for Metastatic Breast Cancer, H1 2015
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
AlphaVax, Inc.
Amarna Therapeutics B.V.
Amgen Inc.
AngioGenex, Inc.
Aphios Corporation
arGEN-X BV
Aslan Pharmaceuticals Pte. Ltd.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bavarian Nordic A/S
Bayer AG
BIOCAD
Biocon Limited
BioMarin Pharmaceutical Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CASI Pharmaceuticals Inc.
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Corcept Therapeutics Incorporated
Curadis GmbH
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
Dompe Farmaceutici S.p.A.
Eisai Co., Ltd.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Etubics Corporation
Eureka Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Galileo Research s.r.l.
Genentech, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
Glycotope GmbH
GTx, Inc.
Hospira, Inc.
Immune Design Corp.
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Immupharma Plc
Imugene Limited
Inbiopro Solutions Pvt. Ltd.
Incyte Corporation
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kancera AB
Karyopharm Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Mabion SA
MacroGenics, Inc.
MandalMed, Inc.
Meabco A/S
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merus B.V.
MetaStat, Inc.
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NanoCarrier Co., Ltd.
Natco Pharma Limited
Nektar Therapeutics
NewLink Genetics Corporation
Nippon Kayaku Co., Ltd.
Northwest Biotherapeutics, Inc.
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Pharmaceuticals, Inc.
Paras Biopharmaceuticals Finland Oy
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Polyphor Ltd.
Prima BioMed Ltd.
Puma Biotechnology, Inc.
Radius Health, Inc.
Samyang Holdings Corporation
Seattle Genetics, Inc.
Sorrento Therapeutics, Inc.
Starpharma Holdings Limited
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Syndax Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Theracrine, Inc.
Tiziana Life Sciences Plc
Transgene Biotek Limited
Vaxil Bio Therapeutics Ltd.
Verastem, Inc.
Vertex Pharmaceuticals Incorporated
VioQuest Pharmaceuticals, Inc.
Wilex AG
WntResearch AB
ZIOPHARM Oncology, Inc.
Zymeworks Inc.
Zyngenia, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • C.R. Bard, Inc.
  • GlaxoSmithKline PLC
  • Hologic Inc.
  • Provista Diagnostics, Inc.
  • Roche Diagnostics Ltd.
  • Genomic Health Inc.